|Mr. Matthew Craig Kapusta||CEO, Interim CFO & Exec. Director||883.62k||N/A||1972|
|Dr. Scott T. McMillan||Chief Operations Officer||595.6k||N/A||1959|
|Ms. Maria E. Cantor||Sr. VP of Investor Relations & Communication||491.12k||N/A||1968|
|Mr. Jonathan Garen||Chief Bus. Officer||560.13k||N/A||1966|
|Dr. Alexander E. Kuta Ph.D.||Sr. VP of Regulatory Affairs||594.99k||N/A||1960|
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure. In addition, the company engages in developing AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment hemophilia A; AMT-190, a differentiated gene therapy for the treatment of Fabry disease; and AMT-150, a gene therapy for SCA3, a central nervous system disorder. The company has collaboration and license agreements with Bristol Myers-Squibb; 4D Molecular Therapeutics, LLC; and Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
uniQure N.V.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.